NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 6th August

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Dr Alistair Patton Present for all items
4. Dr Andrew Makin Present for all items
5. Dr Bushra Hasnie Present for all items
6. Dr Daniel Gallacher Present for all items
7. Dr Francis Drobniewski Present for all items
8. Dr Rhiannon Owen Present for all items
9. Dr Sunita Sharma Present for all items
10. Dr Veline L’Esperance Present for all items
11. Dr Warren Linley Items 1.1 to 4.2.2

 Items 6.1 to 6.2.2

1. Gabriel Rogers Present for all items
2. Lisa Attrill Present for all items
3. Nigel Westwood Present for all items
4. Peter Wheatley-Price Present for all items
5. Professor David McAllister Present for all items
6. Tony Wootton Present for all items
7. Vanessa Danielson Present for all items

NICE staff (key players) present

Emily Crowe, Associate Director Items 1.1 to 4.2.2

Jeremy Powell, Project Manager Items 1.1 to 4.2.2

Rachel Williams, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Cara Gibbons, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Richard Diaz, Associate Director Items 5.1 to 6.2.2

Thomas Feist, Project Manager Items 5.1 to 6.2.2

Michelle Green, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Anuja Chatterjee, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Alexandra Sampson, Heath Technology Assessment Adviser

 Items 6.1 to 6.2.2

Anita Sangha, Heath Technology Assessment Analyst Items 6.1. to 6.2.2

External assessment group representatives present

Nicky Welton, Bristol Items 1.1 to 4.1.3

Deborah Caldwell, Bristol Items 1.1 to 4.1.3

Dawn Lee, PenTAG Items 5.1 to 5.1.3

Alex Allen, PenTAG Items 5.1 to 5.1.3

Ben Burgess, BMJ-TAG Items 6.1 to 6.1.3

Archie Walters, BMJ-TAG Items 6.1 to 6.1.3

Clinical, Patient & NHS England experts present

Professor Heather O’Mahen, Professor of Perinatal and Clinical Psychology, National Clinical Advisor to NHS England Perinatal Mental Health, clinical expert nominated by NHS England Items 1.1 to 4.1.3

Maria Bavetta, Head of Engagement, Maternal Mental Health Alliance, patient expert nominated by Maternal Mental Health Alliance Items 1.1 to 4.1.3

Anita Kambo, Patient expert invited by NICE Items 1.1 to 4.1.3

Suneil Jain, Professor of clinical oncology, clinical expert, nominated by Pfizer and BUG

 Items 5.1 to 5.1.3

Omi Parikh, Consultant clinical oncologist, clinical expert, nominated by Pfizer

 Items 5.1 to 5.1.3

Holly Knight, Specialist nurse, patient expert, nominated by Prostate Cancer UK

 Items 5.1 to 5.1.3

James Richardson, NHSE national specialty adviser (cancer drugs)

 Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Charles Crawley, welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Anna Pracz, Kemi Gibson, Soon Song, Toby Smith and Mariana Bacelar.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 2nd July
1. **Appraisal of Zuranolone for treating postnatal depression [ID6431]**
	1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Biogen.
		2. The chair asked all committee members and clinical and patient experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11356).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Tony Wootton (lay), Bushra Hasnie (clinical) and Warren Linley (cost).
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11356>.
1. **Appraisal of Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]**
	1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pfizer.
		2. The chair asked all committee members and clinical and patient experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10904).
		3. The Chair, Charles Crawley, led a discussion of the evidence presented to the committee. This information was presented to the committee by Nigel Westwood (lay), Peter Wheatley Price (clinical), and Veline L'Esperance (cost).
	2. Part 2 – Closed session (company representatives, clinical and patient professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10904>.
1. **Appraisal of Delgocitinib for treating moderate to severe chronic hand eczema [ID6408]**
	1. Part 1 – Open session
		1. The chair, Baljit Singh, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Leo Pharma.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11506).
		3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Baljit Singh.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11506>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 3rd September and will start promptly at 9:00.